PubRank

G Giovannoni

Author PubWeight™ 93.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000 2.84
2 A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009 2.58
3 Streptococcal infection, Tourette syndrome, and OCD: is there a connection? Neurology 2009 2.33
4 The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 2.17
5 Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009 2.10
6 Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002 2.08
7 Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006 2.04
8 Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009 1.93
9 Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2011 1.70
10 Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child 2004 1.67
11 MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007 1.56
12 Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 2003 1.51
13 Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007 1.45
14 Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Mult Scler 2011 1.43
15 Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis. Eur Neurol 2005 1.38
16 Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 2002 1.38
17 Late recurrences of Sydenham's chorea are not associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004 1.32
18 The evidence for a role of B cells in multiple sclerosis. Neurology 2012 1.32
19 Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012 1.25
20 A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003 1.24
21 Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002 1.13
22 Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol 2010 1.13
23 Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005 1.11
24 Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008 1.10
25 An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004 1.07
26 Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005 1.07
27 Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 2001 1.06
28 Is it multiple sclerosis or not? Neurology 2001 1.06
29 Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011 1.05
30 Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004 1.05
31 Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999 1.04
32 CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004 1.03
33 Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect 2000 1.01
34 Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 2006 0.99
35 EFNS guidelines on disease-specific CSF investigations. Eur J Neurol 2009 0.99
36 Anti-basal ganglia antibodies in patients with atypical dystonia and tics: a prospective study. Neurology 2004 0.99
37 Dyskinesias and associated psychiatric disorders following streptococcal infections. Arch Dis Child 2004 0.98
38 The Bradykinesia Akinesia Incoordination Test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord 2000 0.98
39 Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 2003 0.97
40 Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2007 0.97
41 Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004 0.97
42 Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 0.97
43 Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. Eur J Neurol 2013 0.95
44 HLA-DRB1 and month of birth in multiple sclerosis. Neurology 2009 0.94
45 Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013 0.93
46 Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm Infect 2000 0.93
47 Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005 0.92
48 Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry 2006 0.91
49 Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci 2003 0.91
50 A dystonic syndrome associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004 0.91
51 Could antiretroviral drugs be effective in multiple sclerosis? A case report. Eur J Neurol 2011 0.90
52 Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol 2015 0.89
53 Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. J Neurol Neurosurg Psychiatry 2006 0.89
54 The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 2006 0.88
55 Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003 0.87
56 Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006 0.85
57 Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2007 0.84
58 Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Mult Scler 2009 0.84
59 Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011 0.83
60 Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF. J Neurol Sci 2001 0.82
61 Soluble adhesion molecules in Gilles de la Tourette's syndrome. J Neurol Sci 2005 0.81
62 Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis. J Neuroimmunol 2002 0.81
63 Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004 0.81
64 Streptococcal infection, Tourette syndrome, and OCD: is there a connection? PANDAS: horse or zebra? Neurology 2010 0.80
65 Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. Immunol Today 2000 0.80
66 Pretreatment of astrocytes with interferon-alpha/beta impairs interferon-gamma induction of nitric oxide synthase. J Neurochem 1997 0.79
67 Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2004 0.79
68 Immunological surrogate markers of disease activity in multiple sclerosis. Electroencephalogr Clin Neurophysiol Suppl 1999 0.78
69 Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? Clin Exp Immunol 2012 0.78
70 Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand 2013 0.78
71 Anti-basal ganglia antibodies and Tourette's syndrome: a voxel-based morphometry and diffusion tensor imaging study in an adult population. J Neurol Neurosurg Psychiatry 2008 0.78
72 Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis. Mult Scler 2010 0.78
73 Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis--are we there yet? Mult Scler 2007 0.78
74 Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis. J Neurol Neurosurg Psychiatry 2007 0.77
75 Tracing Sydenham's chorea: historical documents from a British paediatric hospital. Arch Dis Child 2005 0.77
76 Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology 2006 0.76
77 Tumefactive neuro-Behcet disease. Neurology 2004 0.76
78 Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol 2012 0.76
79 Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler 2013 0.76
80 Unihemispheric cerebral vasculitis mimicking Rasmussen's encephalitis. Neurology 2002 0.75
81 Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis? J Neurol Neurosurg Psychiatry 2004 0.75
82 Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis. Mult Scler 2004 0.75
83 Seroprevalence of herpes simplex virus type 2 in multiple sclerosis. Acta Neurol Scand 2006 0.75
84 Urinary neopterin in idiopathic retinal vasculitis. Br J Ophthalmol 2001 0.75
85 Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007 0.75
86 Vitamin D and multiple sclerosis hospital admissions in Scotland. QJM 2011 0.75
87 Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann Neurol 2000 0.75
88 Nitric oxide and headache: related, but how? Cephalalgia 2003 0.75
89 Cerebrospinal fluid S-100b concentrations in patients with HIV infection. AIDS 1999 0.75
90 Clinical use of fructose 1,6-diphosphate. Agressologie 1977 0.75
91 Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients. Eur J Neurol 2006 0.75
92 Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1996 0.75
93 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. J Neuroimmunol 2010 0.75
94 [Differentiated carcinoma of the thyroid]. Minerva Med 1984 0.75
95 Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Mult Scler 2009 0.75
96 Contribution of nitric oxide to exercise-induced hypotension in human sympathetic denervation. Clin Auton Res 1999 0.75
97 Anti-basal ganglia antibodies are absent in patients with primary blepharospasm. Neurology 2002 0.75